AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies.

AbbVie (ABBV) announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, ...

Meghan Markle's As Ever logo includes a tribute to Prince Harry. Inside the symbolism and what the Duchess of Sussex has said ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

the company announced today. He will replace Richard Gonzalez, who has continued to serve as AbbVie’s chairman even after stepping down from the CEO role last July. Gonzalez now plans to fully ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Learn More » AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company ...